The in vitro activity of a new penem antimicrobial agent, CGP 31608, was compared with those of imipenem, SCH 34343, and several other antimicrobial agents against approximately 600 bacterial isolates. CGP 31608 was active against gram-positive organisms, including methicillin-susceptible Staphylococcus aureus (MIC for 90% of the isolates [MIC90], 0.25 ,ug/mI) and penicillin-susceptible streptococci (MIC90s, <2 ,Ig/mI).
Haemophilus influenzae (MIC90s, 0.5 to 1.0 ,ug/mI), and Legionella spp. (MIC90, 2 ,ug/ml). CGP 31608 showed an antibacterial spectrum similar to those of imipenem and SCH 34343 (except that the latter is not active against P. aeruginosa) but was generally less potent than these drugs. However, CGP 31608 demonstrated more activity (MIC90) than imipenem against P. aeruginosa, Pseudomonas cepacia, and methicillin-resistant Staphylococcus epidermidis and S. aureus.
CGP 31608 is a new penem antimicrobial agent which has been selected for study of its potential use in the parenteral therapy of serious infections. Recent reports indicate that the drug is active against a broad range of gram-positive and gram-negative bacteria and resists hydrolysis by a variety of ,-lactamases found in such isolates (7, 13) . In addition, CGP 31608 has been shown to be less susceptible than imipenem to inactivation by human renal dehydropeptidase (0. Zak, E. Batt, W. Tosch, E. A. Konopka, P. Sulc, S. Kunz, M. Lang, and R. Scartazzini, Program Abstr. 26th Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 645, 1986) , which suggests that clinical application of the new penem will not require coadministration of a dehydropeptidase inhibitor.
This study examined the in vitro activity of CGP 31608 in comparison with those of imipenem, SCH 34343 (another penem antibiotic [10] ), and several other antimicrobial agents against approximately 600 bacterial isolates, including strains selected for resistance to other r-lactam antibiotics. The resistance of CGP 31608 to inactivation by plasmidmediated P-lactamases of gram-negative bacteria, as well as to the inducible chromosomal ,B-lactamases found in these organisms, was also investigated.
( Organisms. With few exceptions, the gram-negative bacteria and anaerobic organisms used in this study were clinical isolates collected within the past 4 years at the New England Deaconess Hospital, Boston, Mass. Gram-positive spp. Legionella spp. were tested on a starch-yeast extract medium (9) . Wilkins-Chalgren agar (Oxoid Ltd., Basingstoke, England) was used for studies with Bacteroides fragilis isolates; this was supplemented with 5% sheep blood when other anaerobes were tested (11) .
Inocula were prepared by suspending several colonies in broth to a desired cell density of ca. 107 CFU/ml. The inocula were applied to plates with a multiprong inoculating device (final inoculum, ca. 104 CFU). Plates were incubated in room air at 35°C and read at 18 to 20 h of incubation, except as follows: gonococci were incubated in 5% C02; Legionella spp. were incubated for 48 h; and anaerobes were incubated for 48 h in an anaerobic atmosphere (Oxoid Ltd.).
P-Lactamase induction. The capacity of CGP 31608 to induce production of chromosomal ,-lactamase and the susceptibility of the drug to hydrolysis by this enzyme were studied in five strains each of Serratia marcescens, Enterobacter cloacae, and P. aeruginosa by a disk-approximation technique (6) . Commercially prepared cefoxitin and piperacillin disks were used to document inducibility and susceptibility to enzyme induction, respectively. CGP 31608 was applied to blank paper disks so that each contained 10 ,g of the drug. Disks were placed close together alternately at increasing intervals (0.5-cm increments to allow optimal detection of drug interactions) onto the surface of MuellerHinton agar plates streaked with suspensions of test organisms at a density to yield confluent growth at 18 h of incubation. Drug interactions were assessed by visual inspection of zone sizes in the direction of the approximated disk compared with the zone size along the perpendicular axis.
RESULTS
Susceptibility studies. The comparative activities of CGP 31608 against clinical isolates are shown in Table 1 . Although less active than imipenem and SCH 34343 against methicillin-susceptible Staphylococcus aureus, CGP 31608 was more active than the broad-spectrum cephems against these isolates. Against methicillin-resistant staphylococci, CGP 31608 was the most active P-lactam tested under standard conditions. MICs of the tiew drug against streptococci of groups A, B, C, and G were uniformly within the range of 0.5 to 1.0 ,±g/ml (data for five strains each of groups C and G not shown). Activities of all 3-lactams were lower against penicillin-resistant isolates of pneumococci and viridans group streptococci than against penicillin-susceptible strains of these groups. A significant number of Corynebacterium sp. group JK isolates were resistant (MIC for 90% of the isolates
[MICgo], >128 ,ug/ml) to each of these agents.
Activities of CGP 31608 against facultative gram-negative bacilli were remarkably uniform, with MIC90s of 8 to 16 ,ug/ml. This antimicrobial agent was more active than piperacillin against many isolates, but CGP 31608 was not more active than imipenem or SCH 34343 against any species. CGP 31608 was more active than the other ,Blactams against clinical isolates of P. aeruginosa and Pseudomonas cepacia (MIC90s, 4 Kg/ml). However, Pseudomonas maltophilia isolates were resistant to these drugs (MIC, .-128 ,ug/ml).
CGP 31608 inhibited nine 3-lactamase-negative and 10 P-lactamase-producing strains of N. gonorrhoeae at concentrations between 0.5 and 8 ,ug/ml (MICgo, 2 ,ug/ml) and 0. cloacae, the zone of inhibition around the penem disk was markedly elongated in the direction of the cefoxitin disk (which itself produced little or no zone of inhibition), indicating a synergistic effect by the combination of the penem and cefoxitin.
DISCUSSION
As with imipenem and SCH 34343, CUP 31608 was found to be active against a broad range of bacterial species. The results of this study are in general agreement with those recently reported by other investigators (7, 13) . Although the new drug appears to offer little advantage compared with the other agents against most of the gram-positive species tested, the greater activity of CGP 31608 in comparison with imipenem and SCH 34343 against methicillin-resistant strains of S. aureus and Staphylococcus epidermidis is notable. Similar findings have been described by Neu et al. (7) . However, whether these observations will be clinically applicable is uncertain. As with other P-lactams, detection of subpopulations of methicillin-resistant S. aureus resistant to CGP 31608 could be enhanced by culture in sodium chloridesupplemented media (H. Chamnbers, M. Sachdeva, F. Stella, C. Hackbarth, and M. A. Sande, 26th ICAAC, abstr. no. 632, 1986). Although successful therapy of infections caused by methicillin-resistant S. aureus with imipenem, despite relatively high MICs, has been reported (4), the effectiveness of such therapy is likely to be dependent on host factors and the size of the bacterial ihoculum encountered.
The activity of CGP 31608 against facultative gramnegative bacilli was remarkably uniform (MIC90s, 8 to 16
p.g/ml). Unlike SCH 34343, which is inactive against P. aeruginosa (10), the new penem exhibited excellent activity against the species, including strains producing plasmidmediated 13-lactamases. CGP 31608 was more active than imipenem, piperacillin, and ceftazidime against P. cepacia; its lack of effectiveness against P. maltophilia was most likely due to production of the imipenem-hydrolyzing zinc metalloenzyme found in this species (8 . than imipenem in vitro, it seems unlikely that this drug would be more effective than imipenem in vivo, unless superior penetration into macrophages could be demonstrated. In summary, the antibacterial spectrum of CGP 31608 is similar to that of imipenem, although the new drug is generally less potent than imipenem, except against P. aeruginosa, P. cepacia, and methicillin-resistant staphylococci. Therefore, the potential major advantages of the new compound in comparison with imipenem will most likely be based on favorable properties relating to pharmacokinetics or metabolism, rather than in vitro activity.
